The controversial nosology of Woringer-Kolopp disease (localized pagetoid reticulosis, unilesional mycosis fungoides) is being clarified by the systematic immunophenotypic and immunogenetic examination of infiltrating lesional T lymphocytes. The clinical course and immunohistochemical characteristics of eight cases of Woringer-Kolopp disease are described.
Lesions measured 0.8×0.5 to 16.0×15.0 cm. Histologically, all cases resembled mycosis fungoides— type cutaneous T-cell lymphoma and phenotypic analysis supported their designation as an epidermotropic T-cell process. Phenotypic aberrancy was not noted on immunohistochemical analysis of paraffin-embedded tissue. Three of four patients with available fresh-frozen tissue specimens demonstrated reduced or absent expression of CD7 (Leu-9) and/or Leu-8, while loss of the pan— T-cell markers CD2, CD3, and CD5 was not observed. Only in half these patients was a lesional predominance of CD4+ T-cells revealed. Germline DNA was detected in a lesional skin specimen obtained from one patient tested for T-cell receptor gene rearrangements. After treatment, the observation of disease-free periods ranging from 18 months to 17 years (mean, 5.9 years) reinforces the view that Woringer-Kolopp disease is a focal pathologic event with a favorable prognosis. No patient experienced a local recurrence or distant spread of the disease.
This and previous studies suggest that Woringer-Kolopp disease is a unique, benign unilesional T-cell lymphoproliferative process with certain histologic and phenotypic similarities to both early epidermotropic mycosis fungoides—type cutaneous T-cell lymphoma and other T-cell lymphoproliferations.(Arch Dermatol. 1995;131:325-329)
Burns MK, Chan LS, Cooper KD. Woringer-Kolopp Disease (Localized Pagetoid Reticulosis) or Unilesional Mycosis Fungoides? An Analysis of Eight Cases With Benign Disease. Arch Dermatol. 1995;131(3):325–329. doi:10.1001/archderm.1995.01690150089018
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: